icon
0%

Leidos Holdings LDOS - News Analyzed: 3,900 - Last Week: 100 - Last Month: 500

β‡— Leidos Holdings LDOS Records Celebrity-Worthy Activity in Bio-Tech Market

Leidos Holdings LDOS Records Celebrity-Worthy Activity in Bio-Tech Market

It has been a busy few months for Leidos Holdings. The company has seen a considerable movement in its stock, LDOS, with shares purchased by major shareholders like Fiduciary Trust Co, Martingale Asset Management, BNP Paribas Financial Markets and Loomis Sayles & Co. Various entities, including Empowered Funds, Charles Schwab Investment Management and Citigroup, have however sold their shares. Leidos stock has been on a rollercoaster, plunging down 5.59% on November 14 and falling 11.7% since its last earnings report. Despite the setbacks, Leidos still remains a favorite among financial pundits, heralded for its sensible debt usage and hailed as a strong value stock and growth stock. The company also registered record growth in Q3 2024, boosting its stock price, and increased dividends, rewarding shareholders. Key contributions to its bullish trend include an increased revenue report of $15.4 billion, an 82 RS Rating indicating market leadership, beneficial AI integration and achieving a record high in the stock market at $188.39. Leidos's future looks promising, with expansion plans such as a strategic partnership with the University of Edinburgh to drive AI and Data Science Innovation.

Leidos Holdings LDOS News Analytics from Wed, 31 Jul 2024 07:00:00 GMT to Sat, 30 Nov 2024 08:35:15 GMT - Rating 5 - Innovation 7 - Information 8 - Rumor -4

The email address you have entered is invalid.